TAA-Specific CTLS for Solid Tumors (TACTASOM)

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

October 31, 2018

Study Completion Date

April 7, 2022

Conditions
Rhabdomyosarcoma
Interventions
BIOLOGICAL

TAA-Specific CTLs

"Patients may be pre-medicated with Benadryl up to 1 mg/kg IV (max 50 mg) and Tylenol 10 mg/kg po (max 650 mg).~Cell Administration: Tumor-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients with stable disease or better will receive up to 6 further doses of CTLs, as long as they continue to show disease stabilization or improvement by RECIST criteria at their 8 week or subsequent evaluations. Each dose will consist of the same number as their second injection or less (if there is not enough product available for the subject's original dose).~Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."

Trial Locations (2)

77030

Houston Methodist Hospital, Houston

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

collaborator

Solving Kids' Cancer

OTHER

collaborator

Pierce Phillips Charity

UNKNOWN

lead

Baylor College of Medicine

OTHER

NCT02239861 - TAA-Specific CTLS for Solid Tumors (TACTASOM) | Biotech Hunter | Biotech Hunter